RxDoctor Payments Data

Victor Maquera, MD

Neurology · Orange Park, FLNPI 1891786059

Payments from drug & device makers

$25,854in general payments, 2019–2025

Across 1,444 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$2K
  • Novartis$2K
  • Eisai Inc.$1K
  • EMD Serono, Inc.$1K
  • SK Life Science, Inc.$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$330%
  • Food & beverage$25,46999%
  • Education$3521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)313$3,668
Biogen132$2,104
Novartis94$1,786
Eisai Inc.67$1,366
EMD Serono, Inc.77$1,239
SK Life Science, Inc.56$1,193
UCB, Inc.29$932
Jazz Pharmaceuticals Inc.32$823
Pfizer42$769
Lilly USA, LLC35$735
Lundbeck LLC39$706
Neurelis, Inc.31$648
Sanofi29$567
Takeda Pharmaceuticals U.S.A., Inc.21$551
Argenx US, Inc.23$502
Amgen22$485
Teva Pharmaceuticals USA, Inc.48$480
Axsome Therapeutics, Inc.18$460
Genentech USA, Inc.26$458
ANI Pharmaceuticals, Inc.20$439
Avanir Pharmaceuticals, Inc.25$425
Corium, LLC18$376
Greenwich Biosciences, Inc.19$371
Mallinckrodt Hospital Products Inc.15$369
AstraZeneca14$358
CSL Behring9$293
Otsuka America Pharmaceutical, Inc.13$273
Amneal Pharmaceuticals LLC13$244
Upsher-smith Laboratories LLC11$232
TG Therapeutics, Inc.9$219
Grifols USA, LLC11$189
Scilex Pharmaceuticals Inc.8$173
Johnson & Johnson8$161
Harmony Biosciences LLC7$156
Catalyst Pharmaceuticals, Inc.7$154
Boston Scientific5$140
Impel Pharmaceuticals Inc.7$136
Bristol Myers Squibb7$136
Inspire Medical Systems, Inc.5$114
Sunovion Pharmaceuticals Inc.6$108
E.r. Squibb & Sons, L.L.C.5$95
Almatica Pharma LLC5$74
Biohaven Pharmaceuticals, Inc.3$74
Adamas Pharmaceuticals, Inc.4$73
Kyowa Kirin, Inc.4$66
Banner Life Sciences, LLC4$64
Merck4$63
Tanabe Pharma America, Inc.3$60
Idorsia Pharmaceuticals US Inc3$59
Medtronic3$56
Livanova USA, Inc.3$50
Neurocrine Biosciences, Inc.2$49
Merz Pharmaceuticals, LLC2$44
Globus Medical2$42
Biohaven Pharmaceutical Holding Company Ltd.2$41
Assertio Therapeutics, Inc.2$38
Impel Pharmaceuticals LLC2$34
Arbor Pharmaceuticals, Inc.2$33
Promius Pharma LLC2$33
Acorda Therapeutics, Inc2$33

How this compares

$25,854 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$648,948
Medicare patients
670
Services billed
3,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5020$214,728
Kesimpta PenOfatumumab12$141,776
Glatiramer Acetate20$88,424
CopaxoneGlatiramer Acetate13$75,906
Teriflunomide21$75,372
XcopriCenobamate21$71,732
Nurtec OdtRimegepant Sulfate23$48,844
BotoxOnabotulinumtoxina27$35,857
QuliptaAtogepant19$32,576
Emgality PenGalcanezumab-Gnlm15$13,843
OzempicSemaglutide11$10,484
Dalfampridine ErDalfampridine25$9,037
OxycontinOxycodone Hcl13$8,203
Gabapentin221$7,255
Lidocaine32$5,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$769$263,57243 claims
Teva Pharmaceuticals USA, Inc.Copaxone$480$75,90613 claims
SK Life Science, Inc.Xcopri$1,193$71,73221 claims
AbbVieBotox, Qulipta$3,668$68,43346 claims
Upsher-smith Laboratories LLCTopiramate$232$1,19659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →